Dragana Stanojevic1, Svetlana Apostolovic2,3, Dragana Stokanovic4, Stefan Momčilović5, Tatjana Jevtovic-Stoimenov6, Sonja Salinger-Martinovic2,3, Tomislav Kostic2,3, Valentina N Nikolic4. 1. Clinic for Cardiovascular Diseases, Clinical Centre Nis, Nis, Serbia, draganastanojevic1@gmail.com. 2. Clinic for Cardiovascular Diseases, Clinical Centre Nis, Nis, Serbia. 3. Department of Internal Medicine - Cardiology, Medical Faculty, Nis, Serbia. 4. Department of Pharmacology and Toxicology, Medical Faculty, Nis, Serbia. 5. Medical Faculty, University of Nis, Nis, Serbia. 6. Institute of Biochemistry, Medical Faculty, University of Nis, Nis, Serbia.
Abstract
OBJECTIVE: Atrial fibrillation (AF) is common in acute myocardial infarction (AMI), and galectin-3 is possibly involved in its occurrence. Galectin-3 has been shown to play a central role in fibrosis and tissue remodeling and has a role in inflammatory and proliferative responses. The aim of our study was to measure galectin-3 levels in patients with myocardial infarction and to compare its levels in patients with or without AF, in order to investigate the potential predictive role of galectin-3 in this setting. SUBJECTS AND METHODS: The study included 51 consecutive AMI patients with AF; 27 AMI patients (52.9%) had permanent/persistent AF, and 24 patients (47.1%) had paroxysmal AF. Thirty-eight consecutive AMI patients without AF were used as a control group. Blood samples were obtained from venous blood on the third day after reperfusion. RESULTS: Patients with AF had higher levels of C-reactive protein (p < 0.01) and galectin-3 (p < 0.05) than those without AF. Patients with high galectin-3 had 4.4 times greater odds of having AF. Galectin-3 levels were lower in patients without AF (p < 0.01) than in those with permanent/persistent AF. CONCLUSION: AMI patients with AF had higher levels of galectin-3 than those without this arrhythmia. This biomarker of inflammation and fibrosis could be a potential target for treating AMI patients at high risk.
OBJECTIVE:Atrial fibrillation (AF) is common in acute myocardial infarction (AMI), and galectin-3 is possibly involved in its occurrence. Galectin-3 has been shown to play a central role in fibrosis and tissue remodeling and has a role in inflammatory and proliferative responses. The aim of our study was to measure galectin-3 levels in patients with myocardial infarction and to compare its levels in patients with or without AF, in order to investigate the potential predictive role of galectin-3 in this setting. SUBJECTS AND METHODS: The study included 51 consecutive AMI patients with AF; 27 AMI patients (52.9%) had permanent/persistent AF, and 24 patients (47.1%) had paroxysmal AF. Thirty-eight consecutive AMI patients without AF were used as a control group. Blood samples were obtained from venous blood on the third day after reperfusion. RESULTS:Patients with AF had higher levels of C-reactive protein (p < 0.01) and galectin-3 (p < 0.05) than those without AF. Patients with high galectin-3 had 4.4 times greater odds of having AF. Galectin-3 levels were lower in patients without AF (p < 0.01) than in those with permanent/persistent AF. CONCLUSION: AMI patients with AF had higher levels of galectin-3 than those without this arrhythmia. This biomarker of inflammation and fibrosis could be a potential target for treating AMI patients at high risk.
Authors: Roberto M Lang; Luigi P Badano; Victor Mor-Avi; Jonathan Afilalo; Anderson Armstrong; Laura Ernande; Frank A Flachskampf; Elyse Foster; Steven A Goldstein; Tatiana Kuznetsova; Patrizio Lancellotti; Denisa Muraru; Michael H Picard; Ernst R Rietzschel; Lawrence Rudski; Kirk T Spencer; Wendy Tsang; Jens-Uwe Voigt Journal: J Am Soc Echocardiogr Date: 2015-01 Impact factor: 5.251
Authors: Lili Yu; Willem P T Ruifrok; Maxi Meissner; Eelke M Bos; Harry van Goor; Bahram Sanjabi; Pim van der Harst; Bertram Pitt; Irwin J Goldstein; Jasper A Koerts; Dirk J van Veldhuisen; Ruud A Bank; Wiek H van Gilst; Herman H W Silljé; Rudolf A de Boer Journal: Circ Heart Fail Date: 2012-12-10 Impact factor: 8.790
Authors: R A de Boer; D J van Veldhuisen; R T Gansevoort; A C Muller Kobold; W H van Gilst; H L Hillege; S J L Bakker; P van der Harst Journal: J Intern Med Date: 2011-11-18 Impact factor: 8.989
Authors: Yusuf Selcoki; H İbrahim Aydin; Tugrul H Celik; Ahmet Isleyen; Ali Erayman; M Bora Demircelik; Hilmi Demirin; Aydin Kosus; Beyhan Eryonucu Journal: Clin Invest Med Date: 2016-12-01 Impact factor: 0.825
Authors: E Gucuk Ipek; S Akin Suljevic; H Kafes; F Basyigit; N Karalok; Y Guray; L Dinc Asarcikli; B Acar; H Demirel Journal: Ann Cardiol Angeiol (Paris) Date: 2015-11-24
Authors: Giuseppe Di Tano; Giorgio Caretta; Renata De Maria; Marina Parolini; Laura Bassi; Sophie Testa; Salvatore Pirelli Journal: Heart Date: 2016-07-27 Impact factor: 5.994
Authors: Borja Ibanez; Stefan James; Stefan Agewall; Manuel J Antunes; Chiara Bucciarelli-Ducci; Héctor Bueno; Alida L P Caforio; Filippo Crea; John A Goudevenos; Sigrun Halvorsen; Gerhard Hindricks; Adnan Kastrati; Mattie J Lenzen; Eva Prescott; Marco Roffi; Marco Valgimigli; Christoph Varenhorst; Pascal Vranckx; Petr Widimský Journal: Eur Heart J Date: 2018-01-07 Impact factor: 29.983